ERCC1 and small cell lung carcinoma: Univariate analysis demonstrated that in patients with LS-SCLC high ERCC1 (HR: 1.71, 95% CI: 1.24-2.91; p=0.01), PKM2 (HR: 1.64, 95% CI: 1.17-2.42; p=0.031), TOPOI (HR: 1.41, 95% CI: 1.26-1.98; p=0.044), TOPOIIA (HR: 1.74, 95% CI: 1.33-3.1; p=0.009) and TOPOIIB (HR: 1.82, 95% CI: 1.46-3.18; p=0.004) mRNA expression, the unfavourable expression signature (HR: 4.97, 95% CI: 2.74-7.61; p=0.001), as well as PS of 2 (HR: 1.46, 95% CI: 1.22-2.81; p=0.017) and elevated serum levels of LDH (HR: 1.52, 95% CI: 1.21-2.78; p=0.021) were significantly associated with decreased PFS (Table 3).